AbstractsHead and neck cancer, excluding thyroid1045O - A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)
Head and neck cancer, excluding thyroid
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2018 THE AUTHORS. Published by Elsevier Ltd. All rights reserved.